Do peripheral melatonin agonists improve bone fracture healing? The effects of agomelatine and ramelteon on experimental bone fracture
EUROPEAN JOURNAL OF PHARMACOLOGY, cilt.887, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 887
- Basım Tarihi: 2020
- Doi Numarası: 10.1016/j.ejphar.2020.173577
- Dergi Adı: EUROPEAN JOURNAL OF PHARMACOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, MEDLINE, Veterinary Science Database
- Anahtar Kelimeler: Melatonine, Agomelatine, Ramelteon, Fracture healing, MT2 RECEPTORS, OSTEOPOROSIS
- Atatürk Üniversitesi Adresli: Evet
Özet
Melatonin improves fracture healing, but the long-term use of melatonin seems impracticable in the treatment of fracture due to side effects caused by hormonal stress on chronological rhythm. Ramelteon (RAMEL) and agomelatine (AGO) are non-selective peripheral melatonin receptor (MT) agonists. This study investigated the effects on bone fracture healing of these MT agonists, which do not affect the central nervous system.